VITROLIFE AB |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 183 SEK | -0.57% |
|
+1.82% | -5.29% |
| 22/05 | Sweden's Vitrolife Wraps Up Purchase of Software Group eFertility | MT |
| 22/05 | Vitrolife AB (OM:VITR) acquired Stb Zorg B.V. | CI |
| Sales 2024 * | 364.75Cr 35Cr 2.94TCr | Sales 2025 * | 397.02Cr 38Cr 3.2TCr | Capitalization | 2.49TCr 240.3Cr 20TCr |
|---|---|---|---|---|---|
| Net income 2024 * | 57Cr 5.49Cr 458.49Cr | Net income 2025 * | 67Cr 6.5Cr 543.1Cr | EV / Sales 2024 * | 6.99 x |
| Net Debt 2024 * | 59Cr 5.66Cr 472.71Cr | Net cash position 2025 * | 13Cr 1.23Cr 102.96Cr | EV / Sales 2025 * | 6.24 x |
| P/E ratio 2024 * |
43.8
x | P/E ratio 2025 * |
37
x | Employees | 1,132 |
| Yield 2024 * |
0.64% | Yield 2025 * |
0.75% | Free-Float | 55.35% |
More Fundamentals
* Assessed data
More news
Latest transcript on Vitrolife AB
More press releases
More news
| 1 day | -0.57% | ||
| 1 week | +1.82% | ||
| Current month | -0.16% | ||
| 1 month | +3.89% | ||
| 3 months | -8.71% | ||
| 6 months | +3.71% | ||
| Current year | -5.29% |
1 week
174.80
186.00
1 month
171.20194.30
Current year
156.00205.40
1 year
123.90244.20
3 years
123.90585.00
5 years
112.30585.00
10 years
20.75585.00
| Managers | Title | Age | Since |
|---|---|---|---|
Bronwyn Brophy
CEO | Chief Executive Officer | - | 01/23/01 |
Patrik Tolf
DFI | Director of Finance/CFO | 54 | 01/22/01 |
| Chairman | 68 | 07/15/07 |
| Members of the board | Title | Age | Since |
|---|---|---|---|
| Director/Board Member | 53 | 02/19/02 | |
| Chairman | 68 | 07/15/07 | |
| Director/Board Member | 64 | 27/18/27 |
| Name | Weight | AuM | 1st Jan change | Investor Rating |
|---|---|---|---|---|
| 0.37% | 262 M€ | +8.89% | ||
| 0.02% | 775 M€ | -.--% | - | |
| 0.01% | 10 M€ | -3.35% | - |
| Date | Price | Change | Volume |
|---|---|---|---|
| 13/24/13 | 184.4 | +0.22% | 4 603 |
| 12/24/12 | 184 | +4.72% | 195,528 |
| 11/24/11 | 175.7 | -1.68% | 58,438 |
| 10/24/10 | 178.7 | -1.33% | 30,818 |
| 07/24/07 | 181.1 | -1.36% | 147,988 |
Delayed Quote Nasdaq Stockholm, June 13, 2024 at 02:15 pm IST
More quotes
Vitrolife AB is a Sweden-based company engaged in assisted reproduction services. The Companyâs product portfolio comprises G-RINSE, which is a solution for rinsing of contact materials, EmbryoGlue, which is a human albumin recombinant, ASP, which is a solution for oocyte retrieval and rinsing, and Semen VTS, which is a viscosity treatment system, among others. It also provides a range of procedural solutions for sperm preparation, vitrification, embryo transfer and oocyte retrieval, such as temperature control, condition control, gamete-safe labware and embryo support. The Company is active in Australia, China, France, Italy, Japan, the United States and the United Kingdom, among others, and conducts its business through a number of subsidiaries, such as Vitrolife Ltd., Vitrolife Pty Ltd., and A.T.S. Srl.
Calendar
12/07/2024
- Q2 2024 Earnings Call
Trading Rating
Investor Rating
ESG Refinitiv
B-
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
184
SEK
Average target price
231.7
SEK
Spread / Average Target
+25.91%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -5.29% | 241.87Cr | |
| -2.58% | 826.78Cr | |
| +8.48% | 580.59Cr | |
| +29.76% | 557.62Cr | |
| -15.77% | 385.05Cr | |
| +12.42% | 270.83Cr | |
| -61.85% | 255.58Cr | |
| +23.09% | 213.24Cr | |
| -9.25% | 177.08Cr | |
| -4.76% | 147.51Cr |
- Stock Market
- Equities
- VITR Stock
